Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-31 2024-12-31 2023-11-08 false Information technology consultancy activities 22 0 false true false 15270184 2023-11-07 15270184 2023-11-08 2024-12-31 15270184 2023-01-01 2023-11-07 15270184 2024-12-31 15270184 c:Director5 2023-11-08 2024-12-31 15270184 d:OfficeEquipment 2023-11-08 2024-12-31 15270184 d:OfficeEquipment 2024-12-31 15270184 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-11-08 2024-12-31 15270184 d:PatentsTrademarksLicencesConcessionsSimilar 2024-12-31 15270184 d:ComputerSoftware 2024-12-31 15270184 d:CurrentFinancialInstruments 2024-12-31 15270184 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 15270184 d:ShareCapital 2023-11-08 2024-12-31 15270184 d:ShareCapital 2024-12-31 15270184 d:RetainedEarningsAccumulatedLosses 2023-11-08 2024-12-31 15270184 d:RetainedEarningsAccumulatedLosses 2024-12-31 15270184 c:OrdinaryShareClass1 2023-11-08 2024-12-31 15270184 c:OrdinaryShareClass1 2024-12-31 15270184 c:FRS102 2023-11-08 2024-12-31 15270184 c:Audited 2023-11-08 2024-12-31 15270184 c:FullAccounts 2023-11-08 2024-12-31 15270184 c:PrivateLimitedCompanyLtd 2023-11-08 2024-12-31 15270184 c:SmallCompaniesRegimeForAccounts 2023-11-08 2024-12-31 15270184 d:PatentsTrademarksLicencesConcessionsSimilar d:InternallyGeneratedIntangibleAssets 2023-11-08 2024-12-31 15270184 d:ComputerSoftware d:InternallyGeneratedIntangibleAssets 2023-11-08 2024-12-31 15270184 4 2023-11-08 2024-12-31 15270184 d:InternallyGeneratedIntangibleAssets 2023-11-08 2024-12-31 15270184 d:PatentsTrademarksLicencesConcessionsSimilar d:OwnedIntangibleAssets 2023-11-08 2024-12-31 15270184 d:ComputerSoftware d:OwnedIntangibleAssets 2023-11-08 2024-12-31 15270184 e:PoundSterling 2023-11-08 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 15270184 VITACCESS LIMITED (FORMERLY KNOWN AS MEDICAL BUSINESS RESEARCH LIMITED) FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE PERIOD ENDED 31 DECEMBER 2024
VITACCESS LIMITED REGISTERED NUMBER:15270184
BALANCE SHEET AS AT 31 DECEMBER 2024
|  | 2024
Note |  | £
Fixed assets |  |  |
Intangible assets | 4 |  | 305,497
Tangible assets | 5 |  | 7,500
|  |  | 312,997
Current assets |  |  |
Debtors: amounts falling due within one year | 6 | 792,934 |
Cash at bank and in hand | 7 | 261,015 |
|  | 1,053,949 |
Creditors: amounts falling due within one year | 8 | (1,154,675) |
Net current (liabilities)/assets |  |  | (100,726)
Total assets less current liabilities |  |  | 212,271
Net assets |  |  | 212,271
Capital and reserves |  |  |
Called up share capital |  |  | 318,050
Profit and loss account |  |  | (105,779)
|  |  | 212,271
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 29 September 2025.
M J W Larkin
Director
The notes on pages 3 to 9 form part of these financial statements. Page 1
VITACCESS LIMITED
STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 31 DECEMBER 2024
| Called up share capital | Profit and loss account | Total equity
| £ | £ | £
Comprehensive income for the period |  |  |
Loss for the period | - | (105,779) | (105,779)
Other comprehensive income for the period | - | - | -
Total comprehensive income for the period | - | (105,779) | (105,779)
Contributions by and distributions to owners |  |  |
Shares issued during the period | 318,050 | - | 318,050
Total transactions with owners | 318,050 | - | 318,050
At 31 December 2024 | 318,050 | (105,779) | 212,271
| The notes on pages 3 to 9 form part of these financial statements.
Page 2
VITACCESS LIMITED (FORMERLY KNOWN AS MEDICAL BUSINESS RESEARCH LIMITED)
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2024
1. | General information
Vitaccess Limited is a private company limited by shares and incorporated in England. It commenced trading on 01/01/2024, and it's principal activity is information technology consultancy activities. The company's registered office is: 2nd Floor Nucleus House, 2 Lower Mortlake Road, Richmond, Greater London, England, TW9 2JA. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | Foreign currency translation
Functional and presentation currency The Company's functional and presentational currency is GBP. Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges. Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'. Page 3
VITACCESS LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.3 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Sale of goods Revenue from the sale of goods is recognised when all of the following conditions are satisfied: ∙the Company has transferred the significant risks and rewards of ownership to the buyer; ∙the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the transaction; and ∙the costs incurred or to be incurred in respect of the transaction can be measured reliably. Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably.
| 2.4 | Operating leases: the Company as lessee
Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term. Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.
| 2.5 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument. Page 4
VITACCESS LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.6 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.
| 2.7 | Taxation
Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.
| 2.8 | Exceptional items
Exceptional items are transactions that fall within the ordinary activities of the Company but are presented separately due to their size or incidence.
| 2.9 | Intangible assets
Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years. The estimated useful lives range as follows:
|  |  |  | Purchased Intellectual Property | - | 4 | years
|  |  |  | Software & Databases | - | 4 | years
|  |  |  | Registries | - | 5 | years
| 2.10 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Page 5
VITACCESS LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.10 | Tangible fixed assets (continued)
Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis. Depreciation is provided on the following basis:
|  |  |  | Office equipment | - | 25% |
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
| 2.11 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.12 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.13 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
3. | Employees
| The average monthly number of employees, including directors, during the period was 22.
Page 6
VITACCESS LIMITED (FORMERLY KNOWN AS MEDICAL BUSINESS RESEARCH LIMITED)
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2024
4. | Intangible assets
|  | Patents | Computer software | Total
|  | £ | £ | £
| Cost |  |  |
| Additions - internal | 97,000 | 288,025 | 385,025
| At 31 December 2024 | 97,000 | 288,025 | 385,025
| Amortisation |  |  |
| Charge for the period on owned assets | 24,250 | 55,278 | 79,528
| At 31 December 2024 | 24,250 | 55,278 | 79,528
| Net book value |  |  |
| At 31 December 2024 | 72,750 | 232,747 | 305,497
5. | Tangible fixed assets
|  | Office equipment
|  | £
| Cost or valuation |
| Additions | 10,000
| At 31 December 2024 | 10,000
| Depreciation |
| Charge for the period on owned assets | 2,500
| At 31 December 2024 | 2,500
| Net book value |
| At 31 December 2024 | 7,500
Page 7
VITACCESS LIMITED (FORMERLY KNOWN AS MEDICAL BUSINESS RESEARCH LIMITED)
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2024
6. | Debtors
|  |  |  |  | 2024
|  |  |  |  | £
| Trade debtors | 546,120
| Other debtors | 14,529
| Called up share capital not paid | 117,300
| Prepayments and accrued income | 26,123
| Tax recoverable | 88,862
|  | 792,934
7. | Cash and cash equivalents
|  |  |  |  | 2024
|  |  |  |  | £
| Cash at bank and in hand | 261,015
|  | 261,015
8. | Creditors: Amounts falling due within one year
|  |  |  |  | 2024
|  |  |  |  | £
| Trade creditors | 50,668
| Other taxation and social security | 72,356
| Other creditors | 1,011,633
| Accruals and deferred income | 20,018
|  | 1,154,675
Page 8
VITACCESS LIMITED (FORMERLY KNOWN AS MEDICAL BUSINESS RESEARCH LIMITED)
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2024
9. | Share capital
|  |  |  |  | 2024
|  |  |  |  | £
|  | Allotted, called up and fully paid |
|  | 20,075,000 Ordinary shares of £0.01 each | 200,750
|  | Allotted, called up and partly paid |
|  | 11,730,000 Ordinary shares of £0.01 each | 117,300
The Ordinary shares of £0.01 each carry full voting rights, full dividend rights and full rights to participation in any capital distribution on winding up.
10. | Pension commitments
The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £35,918. Contributions totalling £7,483 were payable to the fund at the reporting date and are included in creditors.
11. | Auditors' information
The auditors' report on the financial statements for the period ended 31 December 2024 was unqualified. The audit report was signed on 29 September 2025 by Ms N A Spoor FCA FCCA (Senior Statutory Auditor) on behalf of White Hart Associates (London) Limited.
Page 9